bevemipretide   Click here for help

GtoPdb Ligand ID: 13258

Synonyms: SBT-272 | SBT272
Compound class: Peptide or derivative
Comment: Bevemipretide is a modified tripeptide (H-DArg-2,6-diMeTyr-Unk, from PubChem) that helps to stabilise the cardiolipin-rich inner mitochondrial membrane and promotes antioxidant, neuroprotective and mitochondria-protective effects in upper motor neurons (UMNs) [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1=C(C[C@@H](C(=O)N[C@@H](CCCCN)C2=NC(=NO2)CC3=CC=CC=C3)NC(=O)[C@@H](CCCN=C(N)N)N)C(=CC(=C1)O)C
Isomeric SMILES CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](CCCCN)C2=NC(=NO2)CC3=CC=CC=C3)NC(=O)[C@@H](CCCN=C(N)N)N)C)O
InChI InChI=1S/C31H45N9O4/c1-19-15-22(41)16-20(2)23(19)18-26(38-28(42)24(33)11-8-14-36-31(34)35)29(43)37-25(12-6-7-13-32)30-39-27(40-44-30)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-26,41H,6-8,11-14,17-18,32-33H2,1-2H3,(H,37,43)(H,38,42)(H4,34,35,36)/t24-,25+,26+/m1/s1
InChI Key XEYINAAYNXIXPY-ZNZIZOMTSA-N
No information available.
Summary of Clinical Use Click here for help
Stealth BioTherapeutics advanced bevemipretide (SBT-272) to early clinical evaluation in 2020 to determine safety and tolerability. It was intended to restore neuronal mitochondrial structure and function in neurodegenerative diseases involving mitochondrial dysfunction. The compound was granted FDA orphan drug status in March 2022 as a treatment for amyotrophic lateral sclerosis (ALS; a.k.a. motor neuron disease or MND). In March 2024, there was no evidence of active SBT-272 clinical trials on ClinicalTrials.gov.